Style | Citing Format |
---|---|
MLA | Zomorodi AR, et al.. "Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study." BMC Infectious Diseases, vol. 24, no. 1, 2024, pp. -. |
APA | Zomorodi AR, Motamedifar M, Rahmanian K, Shakeri M, Hajikhani B, Heidari H, Mansury D, Jahromi AS (2024). Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study. BMC Infectious Diseases, 24(1), -. |
Chicago | Zomorodi AR, Motamedifar M, Rahmanian K, Shakeri M, Hajikhani B, Heidari H, Mansury D, Jahromi AS. "Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study." BMC Infectious Diseases 24, no. 1 (2024): -. |
Harvard | Zomorodi AR et al. (2024) 'Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study', BMC Infectious Diseases, 24(1), pp. -. |
Vancouver | Zomorodi AR, Motamedifar M, Rahmanian K, Shakeri M, Hajikhani B, Heidari H, et al.. Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study. BMC Infectious Diseases. 2024;24(1):-. |
BibTex | @article{ author = {Zomorodi AR and Motamedifar M and Rahmanian K and Shakeri M and Hajikhani B and Heidari H and Mansury D and Jahromi AS}, title = {Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study}, journal = {BMC Infectious Diseases}, volume = {24}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Zomorodi AR AU - Motamedifar M AU - Rahmanian K AU - Shakeri M AU - Hajikhani B AU - Heidari H AU - Mansury D AU - Jahromi AS TI - Investigation of Integron Classes 1, 2, and 3 Among Multi-Drug Resistant Staphylococcus Aureus Isolates in Iran: A Multi-Center Study JO - BMC Infectious Diseases VL - 24 IS - 1 SP - EP - PY - 2024 ER - |